MAZE Maze Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1842295 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-20.1%
TTM EPS YoY32.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-37.5%
ROA-32.4%
ROIC (approx.)-69.0%
Asset turnover—
Leverage & solvency
Liabilities / assets16.2%
Debt / equity0.09x
Current ratio14.14x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $167.50M |
| R&D expense | $108.45M | $83.50M |
| SG&A expense | $34.45M | $26.42M |
| Operating income | -$142.90M | $57.59M |
| Pretax income | -$131.12M | $53.40M |
| Income tax | $0 | $1.17M |
| Net income | -$131.12M | $52.23M |
| EBITDA | -$140.50M | $60.88M |
| EPS (basic) | -3.05 | 1.42 |
| EPS (diluted) | -3.05 | 1.25 |
| Weighted avg. shares (diluted) | 42.98M | 2.73M |
| Balance sheet | ||
| Cash & equivalents | $189.25M | $197.90M |
| Short-term investments | $152.67M | — |
| Current assets | $349.72M | $201.67M |
| PP&E, net | $5.04M | $6.67M |
| Total assets | $397.13M | $240.54M |
| Current liabilities | $22.56M | $20.67M |
| Total liabilities | $42.16M | $43.64M |
| Shareholders' equity | $354.97M | -$311.18M |
| Shares outstanding | 49.34M | 2.45M |
| Cash flow statement | ||
| Operating cash flow | -$111.94M | $75.95M |
| Capital expenditure | $794,000 | $1.15M |
| Free cash flow | -$112.73M | $74.81M |
| Investing cash flow | -$170.96M | -$1.15M |
| Financing cash flow | $275.34M | $92.85M |
| Depreciation & amortization | $2.40M | $3.30M |
| Stock-based compensation | $16.40M | $9.65M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.